CO2023016939A2 - Derivados de exatecán y sus conjugados anticuerpo-fármaco - Google Patents

Derivados de exatecán y sus conjugados anticuerpo-fármaco

Info

Publication number
CO2023016939A2
CO2023016939A2 CONC2023/0016939A CO2023016939A CO2023016939A2 CO 2023016939 A2 CO2023016939 A2 CO 2023016939A2 CO 2023016939 A CO2023016939 A CO 2023016939A CO 2023016939 A2 CO2023016939 A2 CO 2023016939A2
Authority
CO
Colombia
Prior art keywords
exatecan
derivatives
antibody
drug conjugates
novel
Prior art date
Application number
CONC2023/0016939A
Other languages
English (en)
Spanish (es)
Inventor
Marija Vrljic
Peter Strop
Janica Cheuk-Ying Wong
Jaume Pons
Original Assignee
Alx Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alx Oncology Inc filed Critical Alx Oncology Inc
Publication of CO2023016939A2 publication Critical patent/CO2023016939A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CONC2023/0016939A 2021-05-07 2023-12-05 Derivados de exatecán y sus conjugados anticuerpo-fármaco CO2023016939A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163185736P 2021-05-07 2021-05-07
US202163248705P 2021-09-27 2021-09-27
US202263321187P 2022-03-18 2022-03-18
PCT/US2022/028193 WO2022236136A1 (en) 2021-05-07 2022-05-06 Exatecan derivatives and antibody-drug conjugates thereof

Publications (1)

Publication Number Publication Date
CO2023016939A2 true CO2023016939A2 (es) 2024-05-10

Family

ID=81851425

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0016939A CO2023016939A2 (es) 2021-05-07 2023-12-05 Derivados de exatecán y sus conjugados anticuerpo-fármaco

Country Status (15)

Country Link
US (1) US20250101032A1 (https=)
EP (1) EP4334322A1 (https=)
JP (1) JP2024518438A (https=)
KR (1) KR20240036506A (https=)
AU (1) AU2022269073A1 (https=)
BR (1) BR112023023276A2 (https=)
CA (1) CA3219236A1 (https=)
CL (1) CL2023003304A1 (https=)
CO (1) CO2023016939A2 (https=)
GE (1) GEAP202416409A (https=)
IL (1) IL308246A (https=)
MX (1) MX2023013118A (https=)
PE (1) PE20241299A1 (https=)
TW (1) TW202309042A (https=)
WO (1) WO2022236136A1 (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240038138A (ko) 2020-07-13 2024-03-22 리제너론 파마슈티칼스 인코포레이티드 단백질에서 글루타민 잔기에 접합된 캄토테신 유사체 및 그의 용도
MX2023003778A (es) 2020-09-30 2023-04-26 Duality Biologics Suzhou Co Ltd Compuesto antitumoral, metodo de preparacion y uso del mismo.
CN114805377A (zh) * 2021-01-29 2022-07-29 明慧医药（杭州）有限公司 适用于抗体-药物偶联物的毒素分子
AU2022375634A1 (en) 2021-10-25 2024-06-06 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
EP4434548A1 (en) 2021-11-15 2024-09-25 Systimmune, Inc. Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof
US11814394B2 (en) 2021-11-16 2023-11-14 Genequantum Healthcare (Suzhou) Co., Ltd. Exatecan derivatives, linker-payloads, and conjugates and thereof
CA3241734A1 (en) * 2022-01-12 2023-07-20 Amy Han Camptothecin analogs conjugated to a glutamine residue in a protein, and their use
EP4489790A1 (en) * 2022-03-10 2025-01-15 Vivasor, Inc. Antibody-drug conjugates and uses thereof
CN118696048A (zh) * 2022-05-09 2024-09-24 同宜医药（苏州）有限公司 一种喜树碱衍生物，基于其的抗体-药物偶联物和药物组合物，及其应用
KR20250075560A (ko) 2022-07-15 2025-05-28 진콴텀 헬스케어 (쑤저우) 씨오., 엘티디. 항-trop2 항체 및 이의 접합체
KR20250049293A (ko) * 2022-07-27 2025-04-11 밍훼이 파마슈티컬 (항저우) 리미티드 항체-약물 접합체 및 이의 용도
CN117510515A (zh) * 2022-07-28 2024-02-06 明慧医药（杭州）有限公司 适用于抗体-药物偶联物的毒素分子
CN117024438A (zh) * 2022-07-29 2023-11-10 杭州爱科瑞思生物医药有限公司 依沙替康衍生物及其应用
JP2025511436A (ja) * 2022-09-02 2025-04-16 メルク・シャープ・アンド・ドーム・エルエルシー エキサテカン由来トポイソメラーゼ－１阻害薬医薬組成物及びその使用
EP4594327A1 (en) 2022-09-30 2025-08-06 BeiGene Switzerland GmbH Ligand-drug conjugate of exatecan analogue, and medical use thereof
PE20252282A1 (es) * 2022-10-09 2025-09-18 Lanova Medicines Ltd Compuestos, composiciones y metodos
IL320634A (en) * 2022-11-04 2025-07-01 Alx Oncology Inc EXATECAN derivatives and antibody-drug conjugates
CN119855820A (zh) * 2022-12-16 2025-04-18 上海齐鲁制药研究中心有限公司 喜树碱类化合物及其制备方法和用途
WO2024130161A2 (en) 2022-12-16 2024-06-20 Bionecure Therapeutics Inc Novel camptothecin derivatives and conjugates thereof
IL321193A (en) * 2022-12-28 2025-07-01 Adcendo Aps Antibody-drug conjugates targeting UPARAP including extacan derivatives
CN119630672B (zh) * 2023-02-23 2026-01-30 一线医药（杭州）有限公司 喜树碱衍生物及其偶联物以及其制备方法和医药用途
CN116063311B (zh) * 2023-03-01 2025-09-26 金麦安博生物制药(苏州)有限公司 一种依喜替康衍生物及其制备方法
CN120916790A (zh) * 2023-03-27 2025-11-07 台湾浩鼎生技股份有限公司 Trop2耦合生物分子、医药组合物及方法
TW202438069A (zh) * 2023-03-30 2024-10-01 大陸商上海齊魯製藥研究中心有限公司 依喜替康衍生物及其抗體藥物偶聯物
EP4687996A1 (en) * 2023-04-05 2026-02-11 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
EP4687997A2 (en) * 2023-04-05 2026-02-11 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
EP4687995A1 (en) * 2023-04-05 2026-02-11 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
US20240398794A1 (en) 2023-04-07 2024-12-05 Terns Pharmaceuticals, Inc. COMBINATIONS OF GLP-1R AND THRß AGONISTS AND METHODS OF USE THEREOF
WO2024227432A1 (zh) * 2023-04-30 2024-11-07 泰诚思(上海)生物医药有限公司 喜树碱衍生物、其制备方法及用途、抗体药物偶联物及其应用
CN119080792A (zh) * 2023-09-15 2024-12-06 杭州爱科瑞思生物医药有限公司 依沙替康羟胺衍生物及其应用
CN120641100A (zh) * 2023-09-22 2025-09-12 台湾浩鼎生技股份有限公司 用于抗体耦合的改良型连接符-负载物、医药组合物、及其应用
CN117417347A (zh) * 2023-09-28 2024-01-19 杭州爱科瑞思生物医药有限公司 卤素取代的依沙替康的酰胺衍生物及其制备方法和应用
CN117645608A (zh) * 2023-11-30 2024-03-05 昆山新蕴达生物科技有限公司 抗体药物偶联物及其应用
WO2025141153A1 (en) * 2023-12-29 2025-07-03 Oncomatryx Biopharma, S.L. Endo180 targeted antibody-drug conjugates
CN117986269A (zh) * 2024-01-18 2024-05-07 苏州提领生物制药有限公司 喜树碱衍生物及其制备方法和应用
WO2025167722A1 (zh) * 2024-02-06 2025-08-14 四川科伦博泰生物医药股份有限公司 稠环化合物及其制备方法和应用
WO2025207828A1 (en) * 2024-03-26 2025-10-02 Fulgent Pharma Llc Nanocomposition comprising modified exatecan and use thereof
WO2025233501A1 (en) * 2024-05-10 2025-11-13 Astrazeneca Ab Conjugates comprising a topoisomerase i inhibitor
WO2025247302A1 (zh) * 2024-05-31 2025-12-04 杭州中美华东制药有限公司 一种喜树碱类化合物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3466976T1 (sl) * 2014-01-31 2021-12-31 Daiichi Sankyo Company, Limited Anti-her2 konjugat protitelesa-zdravila
JP6612738B2 (ja) * 2014-04-10 2019-11-27 第一三共株式会社 抗ｈｅｒ２抗体−薬物コンジュゲート
WO2020063676A1 (zh) * 2018-09-26 2020-04-02 江苏恒瑞医药股份有限公司 依喜替康类似物的配体-药物偶联物及其制备方法和应用
CN111620927B (zh) * 2019-05-20 2022-11-11 烟台迈百瑞国际生物医药股份有限公司 一种抗体药物偶联物中间体的一锅法制备工艺
CN111689980A (zh) * 2019-05-26 2020-09-22 四川百利药业有限责任公司 一种喜树碱药物及其抗体偶联物
CN112125915A (zh) * 2019-09-18 2020-12-25 四川百利药业有限责任公司 一种喜树碱衍生物及其偶联物
MX2023003778A (es) 2020-09-30 2023-04-26 Duality Biologics Suzhou Co Ltd Compuesto antitumoral, metodo de preparacion y uso del mismo.

Also Published As

Publication number Publication date
CA3219236A1 (en) 2022-11-10
MX2023013118A (es) 2024-02-27
US20250101032A1 (en) 2025-03-27
TW202309042A (zh) 2023-03-01
EP4334322A1 (en) 2024-03-13
JP2024518438A (ja) 2024-05-01
GEAP202416409A (en) 2024-02-26
AU2022269073A1 (en) 2023-11-23
KR20240036506A (ko) 2024-03-20
CL2023003304A1 (es) 2024-04-19
WO2022236136A1 (en) 2022-11-10
PE20241299A1 (es) 2024-06-24
BR112023023276A2 (pt) 2024-01-30
IL308246A (en) 2024-01-01

Similar Documents

Publication Publication Date Title
CO2023016939A2 (es) Derivados de exatecán y sus conjugados anticuerpo-fármaco
MX2022006893A (es) Conjugado anticuerpo-farmaco anti-claudina y uso farmaceutico del mismo.
MX2025005197A (es) Derivados de exatecan y conjugados de anticuerpo y farmaco de estos
MX2019005879A (es) Enlazadores que contienen peptido para conjugados anticuerpo-farmaco.
WO2020236841A3 (en) Antibody drug conjugates having linkers comprising hydrophilic groups
DOP2020000119A (es) Conjugados anticuerpo anti-cd40-fármaco
BR112023014128A2 (pt) Conjugados de anticorpo-fármaco imunomodulatórios
EA202090148A1 (ru) Пирролобензодиазепиновые конъюгаты
CO2019006455A2 (es) Conjugados anticuerpo-droga para ablación de células madre hematopoyéticas
MX2021008708A (es) Formulaciones farmaceuticas secas de conjugados de peptido natriuretico tipo c (cnp).
JOP20230238A1 (ar) مترافقات إكساتيكان جسم مضاد ضد نيكتين-4
CO2024012877A2 (es) Conjugados de fármaco-anticuerpo dirigidos al receptor de folato alfa y métodos de uso
CL2022003411A1 (es) Conjugados anticuerpo biespecífico-fármaco dirigidos a egfr y muc1 y sus usos
CO2023012358A2 (es) Conjugados de amatoxina y anticuerpo específicos de linfocitos b
MX2022008437A (es) Conjugados fármaco-anticuerpo específicos de sitio con enlazadores que contienen péptidos.
CL2023001266A1 (es) Composición que comprende una combinación de inhibidor de punto de control inmunitario
MX2025003695A (es) Conjugados de anticuerpo y farmaco que se dirigen a napi2b y metodos de uso
CL2024003441A1 (es) Conjugados anticuerpo-fármaco 5t4 y usos de los mismos
AR115571A1 (es) Conjugados anticuerpo droga para ablación de células madre hematopoyéticas
CL2023003905A1 (es) Conjugados novedosos que comprenden fosfoantígenos y su uso terapéutico
CO2025004508A2 (es) Conjugados de anticuerpo-farmaco dirigidos a glipicano-3 y métodos de uso
MX2024008361A (es) Derivados de verrucarina a y conjugados anticuerpo-fármaco de los mismos.
AR134425A1 (es) Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos
PY24103486A (es) Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos
PE20210861A1 (es) Formulaciones de dendrimeros